Ulivi Paola, Passardi Alessandro, Marisi Giorgia, Chiadini Elisa, Molinari Chiara, Canale Matteo, Pasini Luigi, Ferroni Fabio, Frassineti Giovanni Luca, Bartolini Giulia, Monti Manlio
Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola (FC), Italy.
Medical Oncology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola (FC), Italy.
Front Pharmacol. 2021 Nov 10;12:745701. doi: 10.3389/fphar.2021.745701. eCollection 2021.
Liquid biopsy represents a valid strategy for tumor molecular characterization. It gives the opportunity to bypass tumor heterogeneity, to monitor tumor characteristics during the course of treatment, and to perform the analysis even when tumor tissue is not available or inadequate. In the clinical practice of metastatic colorectal cancer, tumor molecular characterization is crucial for patient management, as and status could influence the treatment choice. Although for this type of cancer tumor tissue is usually available at diagnosis, liquid biopsy could give complementary information and could permit monitoring of the mutation status during the course of treatment. At present, there are no clinical indications for its use in clinical practice. However, we report four clinical cases for which liquid biopsy analysis gave integrative information with respect to tumor tissue characterization, which permits us to understand the unresponsiveness of patients to treatment, with potential implications in patient's management.
液体活检是肿瘤分子特征分析的一种有效策略。它为绕过肿瘤异质性、在治疗过程中监测肿瘤特征以及即使在肿瘤组织无法获取或不足时进行分析提供了机会。在转移性结直肠癌的临床实践中，肿瘤分子特征分析对患者管理至关重要，因为[此处原文缺失两个关键状态信息，无法准确翻译]状态可能会影响治疗选择。虽然对于这类癌症，肿瘤组织通常在诊断时即可获取，但液体活检可以提供补充信息，并允许在治疗过程中监测突变状态。目前，其在临床实践中尚无临床应用指征。然而，我们报告了四个临床病例，在这些病例中，液体活检分析提供了关于肿瘤组织特征的综合信息，这使我们能够理解患者对治疗无反应的情况，对患者管理具有潜在意义。
